MaxCyte’s technology was developed for the clinic.
- Produce complex antigens, virus like particles (VLPs), and viral vectors in weeks not months
- Produce diagnostic antibodies for your vaccine avoiding commercial limitations
- Scale seamlessly from discovery to phase I clinical with a single technology
- Achieve reproducibility and technology consistency avoiding time consuming re-
optimization through each phase
- Transient and stable cell line development strategies can be employed simultaneously
- MaxCyte is the only electroporation platform with a clear regulatory pathway, saving more
time as you move into the clinic.
- High Loading Efficiency
- High Cell Viability
- Technology Consistency
- A Regulatory Pathway
- Licenses granted to 100+ cell therapy programs, 70+ are licensed for clinical use
- In-lab scientific expertise